Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The interaction of quaternary reversible acetylcholinesterase inhibitors with the nicotinic receptor

V. Sepsova, J. Krusek, J. Zdarova Karasova, F. Zemek, K. Musilek, K. Kuca, O. Soukup

. 2014 ; 63 (6) : 771-777. [pub] 20140826

Language English Country Czech Republic

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15030728

Acetylcholinesterase inhibitors (AChEIs) are used in the treatment of myasthenia gravis (MG). We investigated the effects of AChEIs on peripheral nicotinic receptors (nAChR), which play a crucial role in the treatment of MG symptoms. The positive modulation of those receptors by AChE inhibitors could have an added value to the anti-AChE activity and might be useful in the therapy of MG. Furthermore, to estimate the potential drawbacks of the compounds, cytotoxicity has been assessed on various cell lines. The whole-cell mode of the patch-clamp method was employed. The experiments were performed on medulloblastoma/rhabdomyosarcoma cell line TE671 expressing human embryonic muscle-like receptor with subunits alpha2betagammadelta. The effect of the compounds on cell viability was measured by standard MTT assay (Sigma Aldrich) on ACHN (renal cell adenocarcinoma), HeLa (immortal cell line derived from a cervical carcinoma), HEPG2 (hepatocellular carcinoma) and BJ (skin fibroblasts) cell lines. No positive modulation by the tested AChE inhibitors was observed. Moreover, the compounds exhibited antagonistic activity on the peripheral nAChR. Standard drugs used in MG treatment were shown to be less potent inhibitors of muscle-type nAChR than the newly synthesized compounds. The new compounds showed very little effect on cell viability, and toxicities were comparable to standards. Newly synthesized AChEIs inhibited peripheral nAChR. Furthermore, the inhibition was higher than that of standards used for the treatment of MG. They could be used for the study of nAChR function, thanks to their high antagonizing potency and fast recovery of receptor activity after their removal. However, since no positive modulation was observed, the new compounds do not seem to be promising candidates for MG treatment, even though their cytotoxic effect was relatively low.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15030728
003      
CZ-PrNML
005      
20151016092257.0
007      
ta
008      
150929s2014 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.932768 $2 doi
035    __
$a (PubMed)25157661
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Hepnarová, Vendula $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic; Biomedical Research Center, Hradec Kralove, Czech Republic $7 xx0216882
245    14
$a The interaction of quaternary reversible acetylcholinesterase inhibitors with the nicotinic receptor / $c V. Sepsova, J. Krusek, J. Zdarova Karasova, F. Zemek, K. Musilek, K. Kuca, O. Soukup
520    9_
$a Acetylcholinesterase inhibitors (AChEIs) are used in the treatment of myasthenia gravis (MG). We investigated the effects of AChEIs on peripheral nicotinic receptors (nAChR), which play a crucial role in the treatment of MG symptoms. The positive modulation of those receptors by AChE inhibitors could have an added value to the anti-AChE activity and might be useful in the therapy of MG. Furthermore, to estimate the potential drawbacks of the compounds, cytotoxicity has been assessed on various cell lines. The whole-cell mode of the patch-clamp method was employed. The experiments were performed on medulloblastoma/rhabdomyosarcoma cell line TE671 expressing human embryonic muscle-like receptor with subunits alpha2betagammadelta. The effect of the compounds on cell viability was measured by standard MTT assay (Sigma Aldrich) on ACHN (renal cell adenocarcinoma), HeLa (immortal cell line derived from a cervical carcinoma), HEPG2 (hepatocellular carcinoma) and BJ (skin fibroblasts) cell lines. No positive modulation by the tested AChE inhibitors was observed. Moreover, the compounds exhibited antagonistic activity on the peripheral nAChR. Standard drugs used in MG treatment were shown to be less potent inhibitors of muscle-type nAChR than the newly synthesized compounds. The new compounds showed very little effect on cell viability, and toxicities were comparable to standards. Newly synthesized AChEIs inhibited peripheral nAChR. Furthermore, the inhibition was higher than that of standards used for the treatment of MG. They could be used for the study of nAChR function, thanks to their high antagonizing potency and fast recovery of receptor activity after their removal. However, since no positive modulation was observed, the new compounds do not seem to be promising candidates for MG treatment, even though their cytotoxic effect was relatively low.
650    _2
$a acetylcholin $x farmakologie $7 D000109
650    12
$a acetylcholinesterasa $7 D000110
650    _2
$a buněčné linie $7 D002460
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cholinesterasové inhibitory $x chemická syntéza $x farmakologie $7 D002800
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a lidé $7 D006801
650    _2
$a membránové potenciály $x účinky léků $7 D008564
650    _2
$a myasthenia gravis $x patofyziologie $7 D009157
650    _2
$a metoda terčíkového zámku $7 D018408
650    _2
$a nikotinové receptory $x účinky léků $7 D011978
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krůšek, Jan, $d 1961- $7 xx0101031 $u Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Žďárová Karasová, Jana, $d 1982- $7 xx0099787 $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
700    1_
$a Zemek, Filip $7 xx0308466 $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
700    1_
$a Musílek, Kamil, $d 1980- $7 xx0135628 $u Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Kuča, Kamil, $d 1978- $7 xx0041831 $u Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Soukup, Ondřej $7 xx0253350 $u Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic
773    0_
$w MED00003824 $t Physiological research Academia Scientiarum Bohemoslovaca $x 1802-9973 $g Roč. 63, č. 6 (2014), s. 771-777
856    41
$u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20150929 $b ABA008
991    __
$a 20151015134552 $b ABA008
999    __
$a ok $b bmc $g 1094176 $s 913841
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 63 $c 6 $d 771-777 $e 20140826 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20150929

Find record

Citation metrics

Archiving options